| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
|
|
Academic Article
|
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
|
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
|
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
|
Academic Article
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
|
Academic Article
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
|
Academic Article
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
|
Academic Article
|
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
|
|
Academic Article
|
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
|
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
|
Academic Article
|
Models of excellence: improving oncology drug development.
|
|
Academic Article
|
Phase I study of escalating does of carboplatin.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
|
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
|
Academic Article
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Analysis of the yield of phase II combination therapy trials in medical oncology.
|
|
Academic Article
|
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
|
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
|
Academic Article
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
|
Academic Article
|
Drug combinations: dangerous liaisons or great expectations?
|
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
|
Academic Article
|
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
|
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
|
Academic Article
|
Preventing adverse drug-drug interactions: a need for improved data and logistics.
|
|
Academic Article
|
Time to tumor growth: a model end point and new metric system for oncology clinical trials.
|
|
Academic Article
|
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
|
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
|
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
|
Academic Article
|
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
|
|
Academic Article
|
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
|
|
Academic Article
|
Dose Optimization of Pembrolizumab: Less May Be More.
|